Beam Therapeutics Inc. [NASDAQ: BEAM] closed the trading session at $35.51 on 10/22/20. The day’s price range saw the stock hit a low of $32.30, while the highest price level was $35.89. The company report on October 2, 2020 that Beam Therapeutics to Participate in Chardan Virtual 4th Annual Genetic Medicines Conference.
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, Oct. 5, 2020 at 8:00 a.m. ET.
Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. We’ll cover the basics of better investing and show you how to give yourself an edge in the market.
GET FREE LESSON outside the norm.
The live webcast will be available in the investor section of the company’s website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.
The stocks have a year to date performance of 89.39 percent and weekly performance of 7.87 percent. The stock has been moved at 95.65 percent over the last six months. The stock has performed 36.11 percent around the most recent 30 days and changed 67.82 percent over the most recent 3-months.
If compared to the average trading volume of 640.21K shares, BEAM reached to a volume of 1598207 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Beam Therapeutics Inc. [BEAM]:
William Blair have made an estimate for Beam Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 05, 2020. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. The new note on the price target was released on March 02, 2020, representing the official price target for Beam Therapeutics Inc. stock. Previously, the target price had yet another raise to $31, while JP Morgan analysts kept a Overweight rating on BEAM stock.
The Average True Range (ATR) for Beam Therapeutics Inc. is set at 2.66, with the Price to Sales ratio for BEAM stock in the period of the last 12 months amounting to 84425.02. The Price to Book ratio for the last quarter was 7.60, with the Price to Cash per share for the same quarter was set at 3.99.
BEAM stock trade performance evaluation
Beam Therapeutics Inc. [BEAM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.87. With this latest performance, BEAM shares gained by 36.11% in over the last four-week period, additionally plugging by 95.65% over the last 6 months .
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BEAM stock in for the last two-week period is set at 67.40, with the RSI for the last a single of trading hit 71.26, and the three-weeks RSI is set at 65.24 for Beam Therapeutics Inc. [BEAM]. The present Moving Average for the last 50 days of trading for this stock 26.72, while it was recorded at 32.05 for the last single week of trading.
Beam Therapeutics Inc. [BEAM]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Beam Therapeutics Inc. [BEAM] shares currently have an operating margin of -417522.22. Beam Therapeutics Inc.’s Net Margin is presently recorded at -435144.44.
Return on Total Capital for BEAM is now -56.46, given the latest momentum, and Return on Invested Capital for the company is -60.12. Return on Equity for this stock declined to -66.67, with Return on Assets sitting at -48.48. When it comes to the capital structure of this company, Beam Therapeutics Inc. [BEAM] has a Total Debt to Total Equity ratio set at 30.95. Additionally, BEAM Total Debt to Total Capital is recorded at 23.63, with Total Debt to Total Assets ending up at 20.01.
Reflecting on the efficiency of the workforce at the company, Beam Therapeutics Inc. [BEAM] managed to generate an average of -$663,780 per employee.Beam Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.00 and a Current Ratio set at 6.00.
Beam Therapeutics Inc. [BEAM]: Insider Ownership positions
There are presently around $960 million, or 63.30% of BEAM stock, in the hands of institutional investors. The top three institutional holders of BEAM stocks are: FMR LLC with ownership of 6,971,912, which is approximately 0% of the company’s market cap and around 1.80% of the total institutional ownership; REDMILE GROUP, LLC, holding 3,356,958 shares of the stock with an approximate value of $119.21 million in BEAM stocks shares; and TEMASEK HOLDINGS (PRIVATE) LTD, currently with $119.12 million in BEAM stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Beam Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 49 institutional holders increased their position in Beam Therapeutics Inc. [NASDAQ:BEAM] by around 2,008,467 shares. Additionally, 16 investors decreased positions by around 1,054,828 shares, while 16 investors held positions by with 23,973,074 shares. The mentioned changes placed institutional holdings at 27,036,369 shares, according to the latest SEC report filing. BEAM stock had 24 new institutional investments in for a total of 268,278 shares, while 7 institutional investors sold positions of 773,954 shares during the same period.